Clinical Trial Update: MCLENA-1: A Clinical Trial for the Assessment of Lenalidomide in Amnestic MCI Patients [Phase 2]

View source ↗

Summary

This clinical trial update notes the completion of a Phase 2 study assessing lenalidomide in amnestic mild cognitive impairment patients.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cognitive Impairment

Drugs mentioned

• Revlimid (lenalidomide)

Snippet

Sponsor: St. Joseph's Hospital and Medical Center, Phoenix | Conditions: Cognitive Impairment, Mild, Cognitive Dysfunction | Phase 2 | Status: COMPLETED